Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Nuvilex, Inc. and Celgene, Corp. Can Both Replace Eli Lilly's Cancer Drug Gemzar

Published: Monday, May 20, 2013
Last Updated: Monday, May 20, 2013
Bookmark and Share
The race is on, and patients with advanced stage, inoperable pancreatic cancer will be the recipients of the winner's treatment.

 Two biotechnology companies are registering impressive data in each of their own pancreatic cancer trials, so impressive in fact, the NYSE's Eli Lilly is surely feeling its long time reign as the current standard single-drug treatment for the disease being threatened. Nuvilex, Inc. and NASDAQ's Celgene Corp. are the two biotech firms applying the heat.

One thing is for sure -- pancreatic cancer drugs are big business. Eli Lilly & Co.'s sales of its blockbuster cancer drug gemcitabine (Gemzar®) have averaged close to $1.5-billion per year globally since its approval back in 1996. Gemzar is the only drug approved by the FDA as a single agent for the treatment of advanced, inoperable pancreatic cancer. According to Indianapolis-based Eli Lilly, Gemzar is a nucleoside analogue that interferes with the process of DNA production; thereby preventing cancer cells from replicating and, in turn, slows or stops tumor growth. The drug is the worldwide standard of care as a single agent for pancreatic cancer, and it is the "base" upon which combination chemotherapy treatments for the disease is being built.

While Gemzar has been the go-to treatment for pancreatic cancer patients for years that might be about ready to change, and the best news of all will be for those who suffer from the tough to treat disease and are in desperate need for better therapies. Both Nuvilex and Celgene are producing better data with their treatments in clinical trials as compared to the data offered up by Gemzar.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Genetic Cause of Rare Allergy
Institute has identified a genetic mutation responsible for a rare form of inherited hives induced by vibratory urticaria.
Mitochondria Shown to Trigger Cell Ageing
An international team of scientists has for the first time shown that mitochondria, the batteries of the cells, are essential for ageing.
Cancer Cells Kill Off Healthy Neighbours
Cancer cells create space to grow by killing off surrounding healthy cells, according to UK researchers working with fruit flies.
Validating the Accuracy of CRISPR-Cas9
IBS Researchers create multiplex Digenome-seq to find errors in CRISPR-Cas9 processes.
Cancer Drug Target Visualized at Atomic Resolution
New study using cryo-electron microscopy shows how potential drugs could inhibit cancer.
Genetic Mechanism Behind Cancer-Causing Mutations
Researchers at Indiana University has identified a genetic mechanism that is likely to drive mutations that can lead to cancer.
"Gene Fusion" Drives Childhood Brain Cancers
Study co-led by Penn scientists highlights potential targets for future cancer therapies.
Enzyme Links Age-Related Inflammation, Cancer
Researchers have shown that an enzyme key to regulating gene expression -- and also an oncogene when mutated -- is critical for the expression of numerous inflammatory compounds that have been implicated in age-related increases in cancer and tissue degeneration.
How to Unlock Inaccessible Genes
An international team of biologists has discovered how specialized enzymes remodel the extremely condensed genetic material in the nucleus of cells in order to control which genes can be used.
Viral Gene Editing System Corrects Genetic Liver Disease
Penn study has implications for developing safe therapies for an array of rare diseases via new gene cut-and-paste methods.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!